retatrutide glucagon agonist Retatrutide, a GIP, GLP-1 and receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Retatrutide 40mg Pen | Triple

The Pyzchiva autoinjector was launched in Europe in May 2025, the first ustekinumab biosimilar in Europe available in a pre-filled pen, with an improved self-administration experience supporting better treatment adherence and quality of life

The length of your session depends on the size of the treatment area, but most patients can expect the appointment to last one to two hours, including the absorption period

Never worry about storage during long commutes, flights, or vacations

Selank is a synthetic heptapeptide, thats a chain of seven amino acids, developed by the Institute of Molecular Genetics of the Russian Academy of Sciences back in the late 90s